Cumberland Pharmaceuticals (CPIX) Proxy filing summary

Executive summary

• Entered into a definitive agreement for Apotex to acquire branded U.S. pharmaceutical assets for $100 million in cash, subject to shareholder approval.

• Transaction includes key FDA-approved products and related equity interests, while retaining pipeline assets and majority stake in Cumberland Emerging Technologies.

• Board unanimously approved the transaction and recommends shareholder approval; fairness opinion provided by financial advisor.

• Transaction aims to unlock value, sharpen focus on orphan drug development, and provide enhanced opportunities for employees.

Voting matters and shareholder proposals

• Shareholder approval by majority of outstanding shares is required to consummate the transaction.

• Voting and Support Agreements executed with directors and executive officers holding ~41% of shares, committing to vote in favor and restrict transfers.

• Proxy statement to be filed and mailed to shareholders ahead of a special meeting.

Board of directors and corporate governance

• Board unanimously approved the transaction and recommends shareholders vote in favor.

• Board retains fiduciary out to consider superior proposals under specified conditions.